bcbs alabama glp 1 coverage GLP-1 weight loss drug demand surges in Delaware Weighs Cutting GLP-1 Coverage

MK-677 programs need improved long-term safety monitoring

The authors of the study concluded that the GLP-1 receptor agonist lixisenatide had a three-point beneficial effect, when compared with placebo, in the change over a 12-month period from a baseline value of approximately 15 points on a 132-point scale measuring motor disability. The active arm improved 0.04 points in the lixisenatide group and worsened 3.04 points in the placebo group

Easy to take capsules and correct dosage

Singh S

However, evidence suggests that the combinations effect is not additive

Pills may widen access, not solve the problem Oral GLP-1s could draw interest from employees who dislike injections or see pills as an easier first step